EMEA-002984-PIP01-21
Key facts
| Active substance |
Terbinafine hydrochloride
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0450/2021
|
| PIP number |
EMEA-002984-PIP01-21
|
| Pharmaceutical form(s) |
Cutaneous solution
|
| Condition(s) / indication(s) |
Treatment of onychomycosis
|
| Route(s) of administration |
Topical use
|
| Contact for public enquiries |
Moberg Pharma AB
Email: info@mobergpharma.se |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|